Aspen Japan said on September 1 that it has completed the takeover of four ethical drug brands from Kyowa Hakko Kirin, including Adriacin (doxorubicin), following its transfer announcement made in July.Aspen took over the marketing authorization for three of the…
To read the full story
Related Article
- Aspen Japan to Take Over 4 Brands from Kyowa Kirin
July 4, 2017
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
- Kei Kaneda Becomes President of Moderna Japan
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





